Cadence Neuroscience is a technology company.
Cadence Neuroscience has raised $41.0M across 2 funding rounds.
Cadence Neuroscience has raised $41.0M in total across 2 funding rounds.
Cadence Neuroscience is an early-stage medtech company developing an implantable neuromodulation therapy device to treat drug-resistant epilepsy, particularly in children, by detecting brain signals and delivering targeted electrical stimulation for seizure reduction.[1][2][3][4] Headquartered in Redmond, WA, and founded in 2017, it serves patients with refractory epilepsy who lack effective options beyond medications or invasive surgery, addressing an unmet need for personalized, less invasive treatments that aim to enable seizure-free lives.[2][3][6] The company has raised $15M in Series A (to operationalize, license from Mayo Clinic, and plan studies) and $26M in Series B (for clinical trials), growing to over 30 employees with clinical partnerships, showing strong momentum toward first-in-human trials.[1][2]
Cadence Neuroscience was founded in 2017 by Kent Leyde (CEO) and Doug Sheffield (CSO), both with deep expertise in neuroscience and neuromodulation, starting with a vision to advance therapies for drug-resistant epilepsy.[2][5] The core technology originated from Mayo Clinic, where it was incubated and clinically evaluated for refractory epilepsy management; Cadence secured an exclusive license to refine and commercialize it.[2][4][6] Early traction included $15M Series A funding to build the team and initiate patient studies, followed by a pivotal $26M Series B in 2023 from investors like Angelini Ventures (with board participation), fueling device development, clinical preparations, and team expansion to over 30 amid growing partnerships.[1][2]
Cadence rides the neuromodulation wave in medtech, leveraging AI-driven biomarkers and closed-loop stimulation amid rising demand for precision therapies in neurological disorders affecting millions—epilepsy impacts 3 million in the U.S. alone, with drug-resistant cases driving massive unmet needs and costs.[2][6] Timing aligns with maturing brain-computer interfaces and regulatory progress in responsive neurostimulation (e.g., FDA-approved precedents), amplified by post-pandemic focus on chronic disease tech and pediatric innovation gaps.[1][3][4] Market forces like aging populations, epilepsy prevalence, and investor interest in biotech devices (evidenced by $41M+ funding) favor Cadence, while its Mayo Clinic ties elevate ecosystem standards, influencing collaborative models in epilepsy care and potentially expanding to central pain or other disorders.[1][2][5]
Cadence is poised for clinical milestones, with Series B fueling first trials and potential FDA pathways, scaling toward commercialization amid a medtech funding rebound.[1][2] Trends like AI-enhanced neuromodulation, pediatric neurotech prioritization, and value-based care will propel growth, possibly extending to adjacent indications per patents.[5] Its influence may evolve from epilepsy pioneer to broader neural circuit modulator, amplifying impact as seizure-free outcomes validate the model—ultimately fulfilling the promise of hope for drug-resistant patients where current options fall short.[3][6]
Cadence Neuroscience has raised $41.0M in total across 2 funding rounds.
Cadence Neuroscience's investors include Jazz Venture Partners, The General Partnership.
Cadence Neuroscience has raised $41.0M across 2 funding rounds. Most recently, it raised $26.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $26.0M Series B | Jazz Venture Partners, The General Partnership | |
| Oct 1, 2019 | $15.0M Series A | Jazz Venture Partners, The General Partnership |